[Linda Kelland]

Patients unaware of the changes in the guidelines from Diabetes Canada and that there are newer classes of diabetic medications that not only decrease blood glucose, but have cardiorenal benefits. Convincing patients to change their existing therapy that may be controlling their blood glucose, but not providing cardiorenal benefits can be difficult at times. The costs of the GLP1 agonists and SGLT2 inhibitors can be a barrier for some patients.